BR112019008762A2 - método para o tratamento de um distúrbio proliferativo mutado em flt3 - Google Patents

método para o tratamento de um distúrbio proliferativo mutado em flt3

Info

Publication number
BR112019008762A2
BR112019008762A2 BR112019008762-1A BR112019008762A BR112019008762A2 BR 112019008762 A2 BR112019008762 A2 BR 112019008762A2 BR 112019008762 A BR112019008762 A BR 112019008762A BR 112019008762 A2 BR112019008762 A2 BR 112019008762A2
Authority
BR
Brazil
Prior art keywords
patient
crenolanib
flt3
treating
genetic abnormalities
Prior art date
Application number
BR112019008762-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Vinay K. JAIN
Original Assignee
Arog Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62020370&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019008762(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arog Pharmaceuticals, Inc. filed Critical Arog Pharmaceuticals, Inc.
Publication of BR112019008762A2 publication Critical patent/BR112019008762A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112019008762-1A 2016-11-02 2017-10-31 método para o tratamento de um distúrbio proliferativo mutado em flt3 BR112019008762A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662416475P 2016-11-02 2016-11-02
US62/416,475 2016-11-02
US15/799,684 US11078541B2 (en) 2016-11-02 2017-10-31 Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
PCT/US2017/059377 WO2018085292A1 (en) 2016-11-02 2017-10-31 Crenolanib for treating flt3 mutated proliferative disorders associated mutations
US15/799,684 2017-10-31

Publications (1)

Publication Number Publication Date
BR112019008762A2 true BR112019008762A2 (pt) 2019-07-16

Family

ID=62020370

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019008762-1A BR112019008762A2 (pt) 2016-11-02 2017-10-31 método para o tratamento de um distúrbio proliferativo mutado em flt3

Country Status (19)

Country Link
US (3) US11078541B2 (cg-RX-API-DMAC7.html)
EP (1) EP3359155A4 (cg-RX-API-DMAC7.html)
JP (3) JP2019532011A (cg-RX-API-DMAC7.html)
KR (2) KR20180074792A (cg-RX-API-DMAC7.html)
CN (1) CN108778276A (cg-RX-API-DMAC7.html)
AU (1) AU2017353925A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019008762A2 (cg-RX-API-DMAC7.html)
CA (1) CA3024012A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001208A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019005466A2 (cg-RX-API-DMAC7.html)
EA (1) EA201991078A1 (cg-RX-API-DMAC7.html)
HK (1) HK1257195A1 (cg-RX-API-DMAC7.html)
IL (1) IL266303A (cg-RX-API-DMAC7.html)
MX (1) MX2019005008A (cg-RX-API-DMAC7.html)
PE (1) PE20191238A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019500965A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201903889TA (cg-RX-API-DMAC7.html)
WO (1) WO2018085292A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201903089B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180074792A (ko) * 2016-11-02 2018-07-03 아로그 파마슈티칼스, 인코퍼레이티드 돌연변이 연관된 flt3 돌연변이된 증식성 장애를 치료하기 위한 크레노라닙
US12534764B2 (en) 2016-11-02 2026-01-27 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
US12662706B2 (en) 2016-11-02 2026-06-23 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
US12268690B2 (en) 2018-07-27 2025-04-08 Oregon Health & Science University Treatments for mutations in acute myeloid leukemia
JP2022503792A (ja) * 2018-09-26 2022-01-12 クラ オンコロジー,インク. メニン阻害剤を用いた血液悪性腫瘍の処置
CN109678849A (zh) * 2019-01-16 2019-04-26 北京悦康科创医药科技股份有限公司 一种抗癌药物的制备方法
US11471451B2 (en) 2019-08-19 2022-10-18 Arog Pharmaceuticals, Inc. Uses of crenolanib
CN110531016B (zh) * 2019-09-05 2021-08-31 合肥诺明药物安全研究有限公司 一种hyml-122血药浓度定量分析方法
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US11524006B2 (en) 2020-09-17 2022-12-13 Arog Pharmaceuticals, Inc. Crenolanib for treating TRK kinase associated proliferative disorders
CN112921091B (zh) * 2021-03-16 2022-01-21 南京先声医学检验实验室有限公司 Flt3基因突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用
JP2023063189A (ja) 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド 以前の治療に対して再発性/不応性のflt3突然変異増殖性障害を治療するためのクレノラニブ
CN115141886B (zh) * 2022-06-28 2023-06-06 厦门艾德生物医药科技股份有限公司 一种基于高通量测序的髓系白血病基因突变检测的探针引物组及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6960590B2 (en) 2000-10-17 2005-11-01 Merck & Co. Inc. Orally active salts with tyrosine kinase activity
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
PT1441737E (pt) 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
DE60205776T2 (de) 2001-12-27 2006-06-14 Theravance Inc Indolinon-derivative als protein-kinasehemmer
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
WO2004039782A1 (ja) 2002-10-29 2004-05-13 Kirin Beer Kabushiki Kaisha Flt3自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
SG148864A1 (en) 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
US7226919B2 (en) 2002-12-18 2007-06-05 Vertex Pharmaceuticals Inc. Compositions useful as inhibitors of protein kinases
DK1641780T3 (da) 2003-06-24 2009-02-02 Pfizer Prod Inc Fremgangsmåder til fremstilling af 1-[(benzimidazol-1yl)quinolin-8-yl]-piperidin-4-ylamin-derivater
EP3354753B1 (en) * 2009-04-06 2020-02-12 Vanda Pharmaceuticals Inc. Method of treatment based on polymorphisms of the kcnq1 gene
CN104508143A (zh) * 2012-03-12 2015-04-08 纪念斯隆-凯特琳癌症中心 用于急性髓细胞白血病的诊断、预后和治疗的方法和组合物
TWI599356B (zh) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型c-kit的方法
BR112015016282A2 (en) 2013-01-07 2017-07-11 Arog Pharmaceuticals, Inc. crenolanib for treatment of mutated flt3 proliferative disorders
KR20180074792A (ko) * 2016-11-02 2018-07-03 아로그 파마슈티칼스, 인코퍼레이티드 돌연변이 연관된 flt3 돌연변이된 증식성 장애를 치료하기 위한 크레노라닙

Also Published As

Publication number Publication date
EP3359155A4 (en) 2019-05-22
JP2022071099A (ja) 2022-05-13
HK1257195A1 (zh) 2019-10-18
WO2018085292A1 (en) 2018-05-11
MX2019005008A (es) 2019-09-10
CN108778276A (zh) 2018-11-09
IL266303A (en) 2019-06-30
CL2019001208A1 (es) 2019-07-26
JP2019532011A (ja) 2019-11-07
JP7536320B2 (ja) 2024-08-20
CO2019005466A2 (es) 2019-07-31
EA201991078A1 (ru) 2019-11-29
US11078541B2 (en) 2021-08-03
PH12019500965A1 (en) 2019-12-02
US12404555B2 (en) 2025-09-02
AU2017353925A1 (en) 2018-09-27
US20250305063A1 (en) 2025-10-02
KR20180074792A (ko) 2018-07-03
ZA201903089B (en) 2019-12-18
SG11201903889TA (en) 2019-05-30
KR20200079351A (ko) 2020-07-02
US20210324481A1 (en) 2021-10-21
CA3024012A1 (en) 2018-05-11
JP2024096859A (ja) 2024-07-17
EP3359155A1 (en) 2018-08-15
PE20191238A1 (es) 2019-09-11
US20180117031A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
PH12019500965A1 (en) Crenolab for treating flt3 mutated proliferative disorders associated mutations
Titus et al. Age-dependent alterations in cAMP signaling contribute to synaptic plasticity deficits following traumatic brain injury
BR112015027682A2 (pt) Uso de sobetirome no tratamento de doenças ou condições associadas com a desmielinização ou mielinização insuficiente
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
Liu et al. Citalopram alleviates chronic stress induced depression-like behaviors in rats by activating GSK3β signaling in dorsal hippocampus
EA201591290A2 (ru) Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
MX2025001920A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
BR112014029338A2 (pt) biomarcadores para determinação da resposta eficaz dos tratamentos de pacientes com carcinoma hepatocelular (hcc)
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
PH12016500842A1 (en) Use of cysteamine and derivatives thereof to treat mitochondrial diseases
BR112017008709A2 (pt) tratamento ou prevenção da anemia em mamíferos não-humanos grávidos
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
MX2024010539A (es) Metodos para tratar enfermedades asociadas con ciliopatias.
BR112023017999A2 (pt) Obicetrapibe para tratamento de demências
Jimenez et al. A phase 2 study to evaluate the effects of cabozantinib in patients with unresectable metastatic pheo-chromocytomas and paragangliomas
BR112019007028A2 (pt) métodos e composições farmacêuticas para o tratamento do câncer renal
BR112016024502A8 (pt) uso de uma dose de partículas finas (fdp) de levodopa na fabricação de um medicamento
Poverennova et al. Diagnosis and treatment of asthenic syndrome in elderly people after acute respiratory viral infection
Lyashenko et al. Melatonin in correction of REM-sleep behavior disorders in Parkinson's disease
MX384453B (es) Métodos in vitro para identificar lactantes prematuros en riesgo de displasia broncopulmonar.
BR112015011394A2 (pt) uso de pidotimod para tratar a dermatite atópica
Comba et al. CSIG-39. Fyn, an oncogene that reduces glioblastoma survival yet sensitizes to chemo-radiotherapy
Mahoney Doxorubicin liposomal

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements